<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875234</url>
  </required_header>
  <id_info>
    <org_study_id>Retro3</org_study_id>
    <nct_id>NCT04875234</nct_id>
  </id_info>
  <brief_title>Vision Improvement for Legally Blind Dry AMD Patients</brief_title>
  <official_title>Vision Improvement for Legally Blind Dry Age-Related Macular Degeneration Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Acuity Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimal Acuity Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective observational study is intended to assess the feasibility of using a&#xD;
      nonsignificant risk device for vision improvement for legally blind dry AMD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective observational study is intended to assess the feasibility of using a&#xD;
      nonsignificant risk device for vision improvement for legally blind dry Age-Related Macular&#xD;
      Degneration patients. 12-month follow-up examinations will be used to assess the amount of&#xD;
      vision improvement and its dependence on device parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best spectacle-corrected distance visual acuity (BCDVA)</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>BCDVA measured using ETDRS eye charts</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <condition>Vision Impairment and Blindness</condition>
  <arm_group>
    <arm_group_label>Legally Blind Dry AMD Patients</arm_group_label>
    <description>Legally Blind Dry AMD Patients with either unilateral or bilateral blindness</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clear-K Low Vision Aid Treatment</intervention_name>
    <description>A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.</description>
    <arm_group_label>Legally Blind Dry AMD Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with dry age-related macular degeneration an legal blindness in one or both eyes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        IInclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Any race&#xD;
&#xD;
          -  Patient is at least 50 years old.&#xD;
&#xD;
          -  Patient must have dry AMD in the study eye.&#xD;
&#xD;
          -  Patient is legally blind due to AMD - i.e., has corrected distance visual acuity&#xD;
             (CDVA) of 20/125 or worse (45 letters; logMAR â‰¥ 0.80) in the study eye.&#xD;
&#xD;
          -  Patient has normal corneal surface topography on videokeratography (i.e., without&#xD;
             distorted or unclear corneal mires).&#xD;
&#xD;
          -  Patient is not a contact lens wearer.&#xD;
&#xD;
          -  Patient is willing and able to comply with all examinations.&#xD;
&#xD;
          -  Patient must be competent to sign an informed consent form before study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Visually significant cataract in the study eye&#xD;
&#xD;
          -  Presence of a visually significant posterior capsule opacity if prior cataract surgery&#xD;
             has been performed in the study eye&#xD;
&#xD;
          -  Any visually significant disease process in any ocular structure other than AMD that&#xD;
             would affect vision in the study eye&#xD;
&#xD;
          -  Previous corneal surgery in the study eye&#xD;
&#xD;
          -  Presence or history of any other condition or finding that, in the opinion of the&#xD;
             investigator, makes the patient unsuitable as a candidate for study participation or&#xD;
             may confound the outcome of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Berry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Acuity Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Berry, PhD</last_name>
    <phone>831-869-1384</phone>
    <email>mberry177@gmail.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD, vision impairment, blindness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

